Sunshine Biopharma Inc. has released its first-quarter results for 2025, reporting an 18% increase in revenues compared to the same period last year. The company's revenues reached $8.9 million, up from $7.54 million in the first quarter of 2024. Despite the revenue growth, Sunshine Biopharma Inc. reported a net loss of $1.18 million, a slight improvement from the $1.28 million net loss reported in the first quarter of the previous year. In addition to the financial results, Sunshine Biopharma appointed a new Chief Commercial Officer, Mr. Michel Roy, and launched six new generic prescription drugs. These include two antibiotics, two drugs for gastrointestinal disorders, and two drugs for schizophrenia. The company also completed additional studies on orthotopic human tumor models in mice, further confirming its K1.1 mRNA Lipid Nanoparticle product as a novel therapeutic agent for human hepatocellular carcinoma. Sunshine Biopharma's CEO, Dr. Steve Slilaty, emphasized the company's commitment to innovation and operational excellence, aiming to expand its product pipeline, strengthen partnerships, and drive long-term sustainable growth.